Literature DB >> 22189846

TCL1A gene involvement in T-cell prolymphocytic leukemia in Japanese patients.

Akihiko Yokohama1, Akio Saitoh, Hirotaka Nakahashi, Takeki Mitsui, Hiromi Koiso, Yoshitora Kim, Hideki Uchiumi, Takayuki Saitoh, Hiroshi Handa, Takahiro Jimbo, Kayoko Murayama, Tohru Sakura, Hirokazu Murakami, Masamitsu Karasawa, Yoshihisa Nojima, Norifumi Tsukamoto.   

Abstract

T-cell prolymphocytic leukemia (T-PLL) is a rare type of peripheral T-cell leukemia. In this study, we examined the clinical and biological characteristics of 11 Japanese patients with T-PLL. Median age was 74 years, with male predominance. Median lymphocyte frequency was 85.3% in blood. Physical characteristics were splenomegaly (36.4%), tiny lymph adenopathy (63.6%), skin lesion (9.1%) and pleural effusion (27.3%). Median survival was 30.1 months, despite treatment with various chemotherapeutic modalities. Although complex chromosomal abnormalities were observed in 5 of 11 cases (45.5%), typical 14q32 and Xq28 abnormalities were not detected. TCL1A mRNA expression was observed in 6 of 11 cases (54.5%) on real-time quantitative PCR. In 5 of these 6 cases, flow cytometric analysis and/or immunohistochemistry confirmed the expression of TCLA1 protein. Split signals for the TCL1 region on fluorescence in situ hybridization confirmed rearrangement in 3 out of 7 cases evaluated. These cases corresponded to cases that were positive for TCL1A expression, suggesting that rearrangement of the TCL1 region induced high expression of TCL1A gene. In summary, a substantial number of T-PLL cases in Japan had abnormal expression of TCL1A, probably due to rearrangement of TCL1 region. Expression and/or rearrangement of TCL1A may, therefore, be a useful marker for diagnosing T-PLL, regardless of chromosomal abnormalities.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22189846     DOI: 10.1007/s12185-011-0986-5

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  36 in total

1.  Concurrent Hodgkin's disease (mixed cellularity type) and T-cell chronic lymphocytic leukemia/prolymphocytic leukemia.

Authors:  A Miyata; K Kojima; T Yoshino; S Fujii; K Shinagawa; K Ichimura
Journal:  Int J Hematol       Date:  2001-02       Impact factor: 2.490

2.  Production of vascular endothelial growth factor in T-cell prolymphocytic leukemia.

Authors:  Toshie Ogasawara; Chisako Narita; Kiyotaka Kawauchi
Journal:  Leuk Res       Date:  2006-04-18       Impact factor: 3.156

3.  T-cell receptor gammadelta T-cell leukemia with the morphology of T-cell prolymphocytic leukemia and a postthymic immunophenotype.

Authors:  T Sugimoto; S Imoto; Y Matsuo; K Kojima; M Yasukawa; T Murayama; J Kohfuku; I Mizuno; K Yakushijin; A Sada; R Nishimura; T Koizumi
Journal:  Ann Hematol       Date:  2001-10-13       Impact factor: 3.673

Review 4.  The TCL1 family of oncoproteins: co-activators of transformation.

Authors:  Michael A Teitell
Journal:  Nat Rev Cancer       Date:  2005-08       Impact factor: 60.716

5.  High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H.

Authors:  C E Dearden; E Matutes; B Cazin; G E Tjønnfjord; A Parreira; B Nomdedeu; P Leoni; F J Clark; D Radia; S M Rassam; T Roques; N Ketterer; V Brito-Babapulle; M J Dyer; D Catovsky
Journal:  Blood       Date:  2001-09-15       Impact factor: 22.113

6.  Abnormalities at 14q32.1 in T cell malignancies involve two oncogenes.

Authors:  Y Pekarsky; C Hallas; M Isobe; G Russo; C M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-16       Impact factor: 11.205

7.  TCL-1, MTCP-1 and TML-1 gene expression profile in non-leukemic clonal proliferations associated with ataxia-telangiectasia.

Authors:  Helen H Chun; Sergi Castellví-Bel; Zhijun Wang; Robert A Nagourney; Susan Plaeger; Sara G Becker-Catania; Faramarz Naeim; Robert S Sparkes; Richard A Gatti
Journal:  Int J Cancer       Date:  2002-02-20       Impact factor: 7.396

8.  Deregulated expression of TCL1 causes T cell leukemia in mice.

Authors:  L Virgilio; C Lazzeri; R Bichi; K Nibu; M G Narducci; G Russo; J L Rothstein; C M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-31       Impact factor: 11.205

9.  High TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemia.

Authors:  Marco Herling; Kaushali A Patel; Michael A Teitell; Marina Konopleva; Farhad Ravandi; Ryuji Kobayashi; Dan Jones
Journal:  Blood       Date:  2007-09-21       Impact factor: 22.113

10.  Multiple karyotypic abnormalities in three cases of small cell variant of T-cell prolymphocytic leukemia.

Authors:  K Heinonen; E Mahlamäki; E Hämäläinen; T Nousiainen; I Mononen
Journal:  Cancer Genet Cytogenet       Date:  1994-11
View more
  3 in total

1.  Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling.

Authors:  E I Andersson; S Pützer; B Yadav; O Dufva; S Khan; L He; L Sellner; A Schrader; G Crispatzu; M Oleś; H Zhang; S Adnan-Awad; S Lagström; D Bellanger; J P Mpindi; S Eldfors; T Pemovska; P Pietarinen; A Lauhio; K Tomska; C Cuesta-Mateos; E Faber; S Koschmieder; T H Brümmendorf; S Kytölä; E-R Savolainen; T Siitonen; P Ellonen; O Kallioniemi; K Wennerberg; W Ding; M-H Stern; W Huber; S Anders; J Tang; T Aittokallio; T Zenz; M Herling; S Mustjoki
Journal:  Leukemia       Date:  2017-08-14       Impact factor: 11.528

2.  Epigenetic therapy overcomes treatment resistance in T cell prolymphocytic leukemia.

Authors:  Zainul S Hasanali; Bikramajit Singh Saroya; August Stuart; Sara Shimko; Juanita Evans; Mithun Vinod Shah; Kamal Sharma; Violetta V Leshchenko; Samir Parekh; Thomas P Loughran; Elliot M Epner
Journal:  Sci Transl Med       Date:  2015-06-24       Impact factor: 17.956

3.  Exploring the molecular pathogenesis associated with T-cell prolymphocytic leukemia based on a comprehensive bioinformatics analysis.

Authors:  Zhangzhen Shi; Jing Yu; Hui Shao; Kailiang Cheng; Jingjie Zhai; Qi Jiang; Hongjun Li
Journal:  Oncol Lett       Date:  2018-05-02       Impact factor: 2.967

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.